Spark Therapeutics CEO and founder Jeff Marrazzo stepping down

23 February 2022
spark-therapeutics-big

Spark Therapeutics, fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease that was acquired by Swiss pharma giant Roche (ROG: SIX) in a $4.8 billion deal in 2020, today announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey Marrazzo as chief executive. Mr Marrazzo, who co-founded the company in 2013, will step down on April 1.

“When I think about Spark’s future, I’ve long viewed Ron as the next person to take over at the helm – not only is he a steadfast leader, he’s been instrumental in developing Spark’s gene therapy pipeline and has a deep understanding of Spark’s unique culture,” said Mr Marrazzo.

“I am incredibly proud of what we’ve built at Spark: from my first meetings in 2011, when the company was merely an idea, to now as the gene therapy center of excellence at one of the largest healthcare companies in the world. I’ve had the remarkable privilege to be part of an incredible team and work on cutting-edge science that has the potential to change people’s lives. Under Ron’s leadership, I know that Spark is well-positioned to deliver on the full promise of gene therapy,” he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology